Guardant Health Inc (GH) Stock Price, Quote & News

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-pow...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 855 698 8887

Fax: 888 974 4258

Website: guardanthealth.com

Address:

3100 Hanover Street, Palo Alto, United States

theoptionsplug Jun. 26 at 12:07 AM

$GH doesn't look like it likes the $52.92 level as we have rejected it all month long The support trendline is probably going to be broken especially with a higher RSI and the 200DMA coming in Obviously, not a sure thing, but I wouldn't play longs here unless there is serious volume and strength which I'm not seeing Wait for a break of structure!

1 · Reply

ZacksResearch Jun. 24 at 8:32 PM

$TEM or $GH — which AI oncology player is the better buy right now? 🤔 Tempus AI boasts a 75.4% revenue growth in Q1 2025, fueled by a $200 million deal with AstraZeneca and Pathos, yet remains unprofitable with an adjusted EBITDA loss. Meanwhile, Guardant Health raised its revenue guidance, driven by strong test demand and improving margins, with non-screening operations excluding Shield on track for breakeven by Q4 2025. See the full investment case here 👉 https://www.zacks.com/commentary/2537259/tem-vs-gh-which-ai-in-precision-oncology-stock-has-more-upside-now?cid=sm-stocktwits-2-2537259-body-28&ADID=SYND_STOCKTWITS_TWEET_2_2537259_BODY_28

0 · Reply

ZacksResearch Jun. 24 at 12:10 PM

$GH vs. $TEM — which AI oncology stock has real upside? GH just raised guidance, is improving margins, and Reveal is gaining traction — all while TEM is still scaling without profits. Full matchup breakdown here 👉 https://www.zacks.com/stock/news/2537259/tem-vs-gh-which-ai-in-precision-oncology-stock-has-more-upside-now?cid=sm-stocktwits-2-2537259-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2537259_TEASER

0 · Reply

DanaBlack Jun. 24 at 2:55 AM

$CRCL $AMD $HOOD $SHOP $GH

1 · Reply

ndsk Jun. 20 at 8:53 PM

$GH AH move of almost 5%. any reason why?

0 · Reply

JFDI Jun. 20 at 5:21 PM

$GH about to go 3wt at range/base highs.

0 · Reply

Monkey_Banana_Genius Jun. 18 at 6:39 PM

$ASTS $GH $NTRA $RKLB $TTWO ❤️🐒🍌🧠. LONG

1 · Reply

Mustardill Jun. 18 at 3:59 PM

$EXAS starting to feel bad for how much this stock lags compared to $GH and $NTRA. Can’t say I didn’t tell you.

2 · Reply

Reanimated666 Jun. 18 at 12:37 PM

$GH Pullback was bought yesterday This is ready for new highs and about to breakout

0 · Reply

WAJeff Jun. 18 at 1:04 AM

Some $GH sold at $52 in ah, $52.98 52 week high in ah

0 · Reply

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Jun 9, 2025, 8:05 AM EDT - 16 days ago

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

Jun 3, 2025, 2:56 PM EDT - 22 days ago

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?

Jun 3, 2025, 8:05 AM EDT - 22 days ago

FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

Jun 2, 2025, 8:05 AM EDT - 23 days ago

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

Jun 2, 2025, 7:00 AM EDT - 23 days ago

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

May 31, 2025, 8:05 AM EDT - 25 days ago

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

May 27, 2025, 5:30 PM EDT - 4 weeks ago

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

May 22, 2025, 5:05 PM EDT - 4 weeks ago

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

May 21, 2025, 8:05 AM EDT - 5 weeks ago

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

May 20, 2025, 8:05 AM EDT - 5 weeks ago

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

May 8, 2025, 4:05 PM EDT - 6 weeks ago

Guardant Health to Participate in Upcoming Investor Conferences

May 8, 2025, 9:20 AM EDT - 6 weeks ago

TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

May 7, 2025, 5:05 PM EDT - 7 weeks ago

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025, 4:33 PM EDT - 7 weeks ago

Guardant Health: Tailwinds Are Beginning To Impact The Financials

Apr 30, 2025, 10:25 PM EDT - 2 months ago

Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 2 months ago

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Apr 29, 2025, 4:20 PM EDT - 2 months ago

Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types

Apr 28, 2025, 9:12 AM EDT - 2 months ago

CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer

Apr 28, 2025, 8:05 AM EDT - 2 months ago

Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer

Apr 24, 2025, 8:05 AM EDT - 2 months ago

Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

PFE

Apr 22, 2025, 8:05 AM EDT - 2 months ago

Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR

Apr 10, 2025, 4:05 PM EDT - 2 months ago

Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

Apr 3, 2025, 8:05 AM EDT - 2 months ago

Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada

Mar 25, 2025, 4:05 PM EDT - 3 months ago

Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries

Mar 13, 2025, 7:51 AM EDT - 3 months ago

Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation

Mar 11, 2025, 2:48 PM EDT - 3 months ago

Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue

Mar 11, 2025, 7:00 AM EDT - 3 months ago

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

Feb 27, 2025, 8:05 AM EST - 4 months ago

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

Feb 21, 2025, 1:33 PM EST - 4 months ago

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

Feb 20, 2025, 11:14 PM EST - 4 months ago

Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:05 PM EST - 4 months ago

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

Feb 13, 2025, 9:45 AM EST - 4 months ago

Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity

Feb 7, 2025, 6:30 AM EST - 4 months ago

Guardant Health Announces Debt Exchange Transactions

Jan 30, 2025, 4:05 PM EST - 5 months ago

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Jan 30, 2025, 8:05 AM EST - 5 months ago

Guardant Health's Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program

Jan 23, 2025, 8:05 AM EST - 5 months ago

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

Jan 21, 2025, 2:15 PM EST - 5 months ago

Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test

Jan 21, 2025, 8:05 AM EST - 5 months ago

Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients

Jan 16, 2025, 8:05 AM EST - 5 months ago

Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

Jan 14, 2025, 3:56 PM EST - 5 months ago

Viz.ai to Collaborate With Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment

Jan 13, 2025, 7:00 AM EST - 5 months ago

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Jan 7, 2025, 8:03 AM EST - 6 months ago

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute's Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

Jan 2, 2025, 4:05 PM EST - 6 months ago

Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 8:05 AM EST - 6 months ago

Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care

Dec 19, 2024, 6:00 AM EST - 6 months ago

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

Dec 18, 2024, 8:05 AM EST - 6 months ago

Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

Dec 9, 2024, 8:05 AM EST - 7 months ago

Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 1:31 PM EST - 7 months ago

Guardant Health Stock Flashing Surefire ‘Buy' Signal

Nov 25, 2024, 5:09 PM EST - 7 months ago

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

NTRA

theoptionsplug Jun. 26 at 12:07 AM

1 · Reply

ZacksResearch Jun. 24 at 8:32 PM

0 · Reply

ZacksResearch Jun. 24 at 12:10 PM

0 · Reply

DanaBlack Jun. 24 at 2:55 AM

$CRCL $AMD $HOOD $SHOP $GH

1 · Reply

ndsk Jun. 20 at 8:53 PM

$GH AH move of almost 5%. any reason why?

0 · Reply

JFDI Jun. 20 at 5:21 PM

$GH about to go 3wt at range/base highs.

0 · Reply

Monkey_Banana_Genius Jun. 18 at 6:39 PM

$ASTS $GH $NTRA $RKLB $TTWO ❤️🐒🍌🧠. LONG

1 · Reply

Mustardill Jun. 18 at 3:59 PM

$EXAS starting to feel bad for how much this stock lags compared to $GH and $NTRA. Can’t say I didn’t tell you.

2 · Reply

Reanimated666 Jun. 18 at 12:37 PM

$GH Pullback was bought yesterday This is ready for new highs and about to breakout

0 · Reply

WAJeff Jun. 18 at 1:04 AM

Some $GH sold at $52 in ah, $52.98 52 week high in ah

0 · Reply

Capitulation_0 Jun. 17 at 6:09 PM

$GH strong.. missed the dip in below $40.. darn.

0 · Reply

Mustardill Jun. 16 at 2:27 PM

$EXAS very impressive how often this goes down. Buy $GH or $NTRA instead!

1 · Reply

Monkey_Banana_Genius Jun. 14 at 10:22 PM

$ASTS $GH $NTRA $RKLB $TTWO so far so good

1 · Reply

LewisDaKat Jun. 14 at 9:25 PM

News Article (GH) Investment Report https://marketwirenews.com/news-releases/-gh-investment-report-7727159621857836.html $GH

0 · Reply

GoldenTradesCapital Jun. 14 at 5:53 PM

🧬 $GH – Cancer Detection at Scale Guardant Health is working to bring liquid biopsy into the mainstream. $GH’s tests are FDA-approved, and partnerships with major hospitals are growing.

0 · Reply

JFDI Jun. 13 at 4:55 PM

$GH nahhh we $HOOD rich bitches.

0 · Reply

Reanimated666 Jun. 13 at 3:13 PM

$GH Fantastic strength and looking for breakout Just entered long here

1 · Reply

Mustardill Jun. 12 at 2:20 PM

$EXAS this stock is ass 😂😂😂 time to sell and buy $GH or $NTRA instead

1 · Reply

RockyMontana Jun. 12 at 12:49 AM

$PSNL $TEM $GRAL $GH $NTRA

0 · Reply

PenkeTrading Jun. 11 at 1:24 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Guardant Health Inc. Is that bullish or bearish? $GH #RsiOverbought #NASDAQ

0 · Reply

Gator5326 Jun. 10 at 12:12 PM

$GH The Shield blood test was also named to TIME’s list of the best inventions of 2024 and selected as a Grand Award Winner in Popular Science’s Best of What’s New 2024 (Health category). Shield is also the first blood test that is FDA approved for primary screening to be included in The National Comprehensive Cancer Network (NCCN) colorectal cancer (CRC) screening guidelines.

0 · Reply

Gator5326 Jun. 10 at 12:10 PM

$GH BOOM! https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZ-2FtX741n0Z6WOyiD4GHhsE2ot5GqmAvyBExw8uY-2BwbjPDESb04kInU28GEi0mEHHbsp0f-2BIBdLqcO-2BCOir0UkxqFQsw7RAdLNI6twcQLNa8MWkuGBkjpYUDZfLxd9WBwvY5dmQREZ2asOuKh4RnSDIcA48YU5Apll5WTFrEFWn51ZXelKPpClVQeo-2BKi7-2BPQhGAthK49kujE-2FfZtl5h2OZc-3DdewJ_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHRgIG36Opi-2BfPD0wkS0BpMtIAo-2BB9AQDngJEBiYQlUQTYv8KzPAZwtPPPutOMqt2Ji3NV9ekyCP6VoI7D-2FaSLgoWTfa8ZERA-2Bp3fzB1IYSLpRG9zadqp81pgSOHzojEJ19osjvfkXPCSM8Biza5dJvYNd2YTNFjXICYGVhqjhksfsso9U5RwzNfaK0rPXNDKulgmmKde4YeNJ6-2Fpa1OIG5X-2BfN-2FM2Dcwl0x6sWoyzYhkvhpfTPibzmpcPAHxZaCpCfle-2BeembZFI0fjPSEh8-2FVi1V2sNJKvXquu8MIMsT0eqmgBZzb1XpKkl58pEogUvg0gjltKgwZz7UD29J5bF9qQ-3D-3D

0 · Reply

Market Cap	6.19B
Revenue (ttm)	739.02M
Net Income (ttm)	-436.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-59.05%
Debt to Equity Ratio	-4.45

Volume	1,667,300
Avg Vol	2,307,194
Day's Range	N/A - N/A
Shares Out	123.89M
Stochastic %K	63%
Beta	1.37
Analysts	Strong Sell
Price Target	$58.73